This week in a remotely conducted hearing in federal court in New Jersey, Purdue Pharma’s chairman, Steve Miller, acknowledged that in order to meet sales goals, the company told the Drug Enforcement Administration that it had created a program to prevent OxyContin from being sold on the black market, even though it was marketing the
China and the U.S. plan to highlight joint efforts to crack down on fentanyl smuggling, addressing an opioid epidemic that President Donald Trump has asked his counterpart Xi Jinping to help alleviate as part of the broader trade talks between Beijing and Washington. China’s National Narcotics Control Commission will hold a press conference Thursday about